Recent Updates
Recently added Catalysts

ABBV-CLS-7262 Dose 1

Phase 2

Amyotrophic Lateral Sclerosis | Small molecule | Neurology |Merit Medical Systems, Inc.|Last Updated: Nov 14, 2025

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment310
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT05740813HEALEY ALS Platform Trial - Regimen F ABBV-CLS-7262PHASE2 COMPLETED 310Mar 23, 2023Oct 3, 2024Nov 14, 20251 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Disease Progression as Assessed by the ALSFRS-R-Slope
Baseline to 24 Weeks

Change in disease severity as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R) total score using a Bayesian repeated measures model that accounts for loss to follow-up due to mortality. Each of 12 questions assessing distinct functional ability is scored from 4(normal) to 0 (no ability), with a maximum total score of 48 and a minimum total score of 0. Participants with higher scores have more physical function. Note that only participants who survived to their Week 24 visit contribute to the estimate.

Mortality Event Rate
Baseline to 24 weeks

Mortality is defined as death or death equivalent. A participant is determined to meet the criteria of death equivalent if permanent assisted ventilation (PAV) is used for more than 22 hours per day for more than seven days in a row. The rate of mortality was estimated from a Bayesian shared-parametric model that assumed exponentially distributed survival times.

Secondary Endpoints
Function by ALSFRS-R Total Score
Baseline to 24 weeks
Respiratory Function
Baseline to 24 Weeks
Upper Limb Muscle Strength
Baseline to 24 weeks
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
ABBV-CLS-7262 Dose 1EXPERIMENTAL -
ABBV-CLS-7262 Dose 2EXPERIMENTAL -
Matching PlaceboPLACEBO_COMPARATOR -
Interventions
NameTypeDescription
ABBV-CLS-7262 Dose 1DRUGABBV-CLS-7262 is administered orally once per day for 24 weeks.
ABBV-CLS-7262 Dose 2DRUGABBV-CLS-7262 is administered orally once per day for 24 weeks.
Matching PlaceboDRUGMatching placebo is administered orally once per day for 24 weeks.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 100 Years
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * No additional inclusion criteria beyond the inclusion criteria specified in the Master Protocol (NCT NCT04297683). Exclusion Criteria: * The following exclusion criteria are in addition to the exclusion criteria specified in the Master Protocol (NCT NCT04297683). 1. Based...

Countries:United States
Unlock Eligibility Criteria